INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a ...

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Shares of Inovio Pharmaceuticals Inc. INO jumped 12.11% to $2.13 Wednesday, on what proved to be an all-around mixed trading ...

PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a biotechnology company with a market capitalization of approximately $69 million, has announced positive results from a Phase 1/2 clinical trial of ...

Inovio (INO) announced that peer-reviewed data from its Phase 1/2 clinical trial with INO-3107 as a potential treatment for recurrent ...

This was the stock's fourth consecutive day of losses.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

During the conference, Dr. Shea and members of INOVIO’s management team will conduct one-on-one meetings with registered investors. A webcast of the presentation will be available on the INOVIO ...